Will the FDA approve an oral LHRH agonist for treatment of prostate cancer? | THE "NEW" PROSTATE CANCER INFOLINK: According to a media release issued yesterday, Myovant Sciences (an Australian company, based in Brisbane) has submitted a New Drug Application (NDA) for approval of its oral LHRH agonist, relugoli…
No comments:
Post a Comment